Adalimumab therapy for psoriasis in real-world practice: Efficacy, safety and results in biologic-naïve vs. non-naïve patients

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 5, 2013, Pages 593-600

  Van Lumig P P M ^a   Van De Kerkhof, P C M ^a   Boezeman, J B M ^a   Driessen, R J B ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID DERIVATIVE; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ADULT; AORTA ANEURYSM; ARTHROPATHY; ARTICLE; BASAL CELL CARCINOMA; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS VARICES BLEEDING; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INTENTION TO TREAT ANALYSIS; LEGIONNAIRE DISEASE; LIVER CIRRHOSIS; LUNG EMBOLISM; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALAISE; MALE; MENORRHAGIA; NEPHROLITHIASIS; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; SIDE EFFECT; SKIN DEFECT; STOMACH PERFORATION; SUBERYTHRODERMIA; THERAPY RESISTANCE; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; WRIST FRACTURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; HUMANS; PROSPECTIVE STUDIES; PSORIASIS;

EID: 84876114248     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04496.x     Document Type: Article

References (28)

1. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH,. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66: 241-251.
2. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
3. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
4. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
5. Ryan C, Kirby B, Collins P, Rogers S,. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin Exp Dermatol 2009; 34: 784-788.
6. Warren RB, Brown BC, Lavery D, Griffiths CE,. Adalimumab for psoriasis: practical experience in a UK tertiary referral centre. Br J Dermatol 2010; 163: 859-862.
7. Martyn-Simmons CL, Green L, Ash G, Groves RW, Smith CH, Barker JN,. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol 2009; 23: 1394-1397.
8. Pitarch G, Sanchez-Carazo JL, Mahiques L, Perez-Ferriols MA, Fortea JM,. Treatment of psoriasis with adalimumab. Clin Exp Dermatol 2007; 32: 18-22.
9. Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM,. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-675.
10. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
11. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ,. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-713.
12. Papoutsaki M, Talamonti M, Giunta A, et al. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by 3-year treatment data on infliximab. Dermatology 2010; 221 (Suppl 1): 43-47.
13. Pitarch G, Sanchez-Carazo JL, Mahiques L, Oliver V,. Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 2008; 216: 312-316.
14. van Vollenhoven RF,. Switching between biological agents. Clin Exp Rheumatol 2004; 22 (5Suppl35): S115-S121.
15. European Medicines Agency. ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. June 1995. URL http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500002749.pdf (last accessed: 9 August 2011).
16. Lecluse LL, Driessen RJ, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146: 127-132.
17. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-926.
18. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007; 57: 269-275.
19. Wolfe F, Michaud K, Dewitt EM,. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 2004; 63 (Suppl 2): ii13-ii17.
20. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
21. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T,. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 2010; 130: 933-943.
22. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007; 56: 3896-3908.
23. Van Lumig PP, Lecluse LL, Driessen RJ, et al. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol 2010; 163: 838-846.
24. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-1096.
25. Ortonne JP, Chimenti S, Reich K, et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol 2011; 25: 1012-1020.
26. Clemmensen A, Spon M, Skov L, Zachariae C, Gniadecki R,. Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25: 1037-1040.
27. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
28. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-1869.